Bexmarilimab (Clevegen) development update
· Cholangiocarcinoma becomes fifth tumour cohort to show early signs of efficacy · Increased bexmarilimab dosing schedule and high baseline regulatory T cell count associated with clinical benefit · High levels of soluble Clever-1 observed in MATINS patients · Soluble Clever-1 has the capacity to suppress T cell activation · Increased bexmarilimab dosing frequency to counter high levels of soluble Clever-1 underway Company announcement, 20 January 2021 at 9.00 AM PM (EEST) Insider information TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)